STAT+: Beyond Wegovy and Ozempic: Biotechs vie for piece of red-hot weight loss market with novel strategies
This is part of a series about new obesity drugs that are transforming patients’ lives, dividing medical experts, and spurring one of the biggest business battles in years. Read more about The Obesity Revolution.
For nearly a decade, Novartis aggressively pursued a drug candidate for muscle disorders, testing it on people with chronic inflammation, elderly people with frailty, hip surgery patients, and other groups.
Continue to STAT+ to read the full story…
